Insider Trading Alert - EXC, IDTI, VRTX, STX And BMR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 11, 2014, 110 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $74.70 to $30,815,350.22.

Highlighted Stocks Traded by Insiders:

Exelon (EXC) - FREE Research Report

DesParte Duane M who is SVP and Controller at Exelon sold 3,000 shares at $29.39 on Feb. 11, 2014. Following this transaction, the SVP and Controller owned 4,671 shares meaning that the stake was reduced by 39.11% with the 3,000-share transaction.

The shares most recently traded at $29.08, down $0.31, or 1.07% since the insider transaction.

The average volume for Exelon has been 7.4 million shares per day over the past 30 days. Exelon has a market cap of $25.2 billion and is part of the utilities sector and utilities industry. Shares are up 7.59% year-to-date as of the close of trading on Tuesday.

Exelon Corporation, a utility services holding company, engages in the energy generation and distribution business in the United States. The stock currently has a dividend yield of 4.22%. The company has a P/E ratio of 11.8. Currently there are no analysts that rate Exelon a buy, 4 analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXC - FREE

TheStreet Quant Ratings rates Exelon as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and poor profit margins. Get the full Exelon Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Integrated Device Technology (IDTI) - FREE Research Report

Waters Gregory L who is President & Ceo at Integrated Device Technology bought 100,000 shares at $10.52 on Feb. 11, 2014. Following this transaction, the President & Ceo owned 100,000 shares meaning that the stake was reduced by 100% with the 100,000-share transaction.

The shares most recently traded at $11.57, up $1.05, or 9.12% since the insider transaction. Historical insider transactions for Integrated Device Technology go as follows:

  • 4-Week # shares sold: 1,891
  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 1,891
  • 24-Week # shares bought: 60,000
  • 24-Week # shares sold: 11,025

The average volume for Integrated Device Technology has been 1.9 million shares per day over the past 30 days. Integrated Device Technology has a market cap of $1.6 billion and is part of the technology sector and electronics industry. Shares are up 8.15% year-to-date as of the close of trading on Tuesday.

Integrated Device Technology, Inc. designs, develops, manufactures, and markets a range of mixed signal semiconductor solutions for the communications, computing, and consumer industries worldwide. It operates in two segments, Communications, and Computing and Consumer. The company has a P/E ratio of 19.9. Currently there are 2 analysts that rate Integrated Device Technology a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IDTI - FREE

TheStreet Quant Ratings rates Integrated Device Technology as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Integrated Device Technology Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Vertex Pharmaceuticals (VRTX) - FREE Research Report

Leiden Jeffrey M who is CEO & President at Vertex Pharmaceuticals sold 35,944 shares at $80.00 on Feb. 11, 2014. Following this transaction, the CEO & President owned 211,481 shares meaning that the stake was reduced by 14.53% with the 35,944-share transaction.

The shares most recently traded at $85.07, up $5.07, or 5.96% since the insider transaction. Historical insider transactions for Vertex Pharmaceuticals go as follows:

  • 4-Week # shares sold: 9,550
  • 12-Week # shares sold: 55,380
  • 24-Week # shares sold: 93,690

The average volume for Vertex Pharmaceuticals has been 1.7 million shares per day over the past 30 days. Vertex Pharmaceuticals has a market cap of $19.2 billion and is part of the health care sector and drugs industry. Shares are up 14.37% year-to-date as of the close of trading on Tuesday.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRTX - FREE

TheStreet Quant Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins and feeble growth in its earnings per share. Get the full Vertex Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Seagate Technology (STX) - FREE Research Report

Cannon Michael R who is Director at Seagate Technology sold 25,228 shares at $49.91 on Feb. 11, 2014. Following this transaction, the Director owned 5,952 shares meaning that the stake was reduced by 80.91% with the 25,228-share transaction.

The shares most recently traded at $49.37, down $0.54, or 1.1% since the insider transaction. Historical insider transactions for Seagate Technology go as follows:

  • 4-Week # shares bought: 1,742
  • 4-Week # shares sold: 4,000
  • 12-Week # shares bought: 1,742
  • 12-Week # shares sold: 15,998
  • 24-Week # shares bought: 1,742
  • 24-Week # shares sold: 219,139

The average volume for Seagate Technology has been 3.6 million shares per day over the past 30 days. Seagate Technology has a market cap of $16.4 billion and is part of the technology sector and computer hardware industry. Shares are down 11.16% year-to-date as of the close of trading on Tuesday.

Seagate Technology Public Limited Company designs, manufactures, and sells electronic data storage products. The stock currently has a dividend yield of 3.45%. The company has a P/E ratio of 11.2. Currently there are 6 analysts that rate Seagate Technology a buy, 1 analyst rates it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STX - FREE

TheStreet Quant Ratings rates Seagate Technology as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Seagate Technology Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

BioMed Realty (BMR) - FREE Research Report

McDevitt Matthew G who is Executive VP, Real Estate at BioMed Realty sold 60,000 shares at $20.28 on Feb. 11, 2014. Following this transaction, the Executive VP, Real Estate owned 145,328 shares meaning that the stake was reduced by 29.22% with the 60,000-share transaction.

The shares most recently traded at $20.25, down $0.03, or 0.16% since the insider transaction.

The average volume for BioMed Realty has been 1.3 million shares per day over the past 30 days. BioMed Realty has a market cap of $3.9 billion and is part of the financial sector and real estate industry. Shares are up 11.76% year-to-date as of the close of trading on Tuesday.

BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT) that focuses on providing real estate to the life science industry in the United States. The stock currently has a dividend yield of 4.97%. The company has a P/E ratio of 100.7. Currently there are 7 analysts that rate BioMed Realty a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMR - FREE

TheStreet Quant Ratings rates BioMed Realty as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and poor profit margins. Get the full BioMed Realty Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Dow Falls Sharply as Apple's Slump Offsets Gains in General Electric

Dow Falls Sharply as Apple's Slump Offsets Gains in General Electric

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Video: How to Select Mutual Funds in Your 401(k)

Video: How to Select Mutual Funds in Your 401(k)

Nucor Is Waiting to See if Steel Tariffs Will Be Implemented, Jim Cramer Says

Nucor Is Waiting to See if Steel Tariffs Will Be Implemented, Jim Cramer Says

Tesla Faces Investigation After Subcontractor Is Injured on the Job

Tesla Faces Investigation After Subcontractor Is Injured on the Job